Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03856593 · ClinicalTrials.gov registry record · NA

Encouraging Judicious Prescribing of Opioids in Los Angeles County

A NA study, sponsored by University of Southern California.

Completed
Registry status
NA
Development phase
541
Enrollment target

NCT03856593: Completed NA study, sponsored by University of Southern California.

NCT03856593 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 541 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03856593, a NA study, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
NA
Development phase
541 participants
Enrollment target

Study Summary

In collaboration with the Los Angeles County Medical Examiner's Office and the State of California's controlled Substance Utilization Review and Evaluation System (CURES), the investigators propose to review opioid poisonings over 12 months and send letters to prescribers in California when at least one of the provider's prescription(s) was filled by a patient who died of an opioid poisoning in Los Angeles County. The letters will be non-judgmental and factual, explaining that a patient of the provider who was being treated with prescription narcotics died of an opioid poisoning. The letters will also encourage judicious prescribing including use of the CURES system before prescribing. The investigators will evaluate physician prescribing practices over 24 months (12 months pre- and 12 months post-letter) using data from the CURES database. The investigators' hypothesis is that letters will make the risk of opioids more cognitively available and that physicians will respond by prescribing opioids more carefully, resulting in fewer deaths due to misuse and more frequent use of the CURES system.

Primary Outcome

Difference in average weekly MME dispensed 52 weeks pre-letter to 4-52 (excludes 0-3 weeks for washout) post-letter. Measure of interest is the difference in the above measure between prescribers randomized to the standard letter and the comparator letter, referred to as the difference-in-difference (interaction coefficient).

Interventions

  • BEHAVIORAL Standard letter
  • BEHAVIORAL Comparator letter

Trial Details

FieldValue
Enrollment Target 541 participants
Start Date 2019-04-05
Est. Completion 2021-08-08
Phase NA
University of Southern California

617 total trials

What the finished NCT03856593 record still lists

NCT03856593 is an interventional study that assigns participants to a tested intervention. The registered 541 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 2 interventions - of which Standard letter is the first listed.

NCT03856593 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03856593 about?

NCT03856593 is a clinical study titled "Encouraging Judicious Prescribing of Opioids in Los Angeles County". In collaboration with the Los Angeles County Medical Examiner's Office and the State of California's controlled Substance Utilization Review and Evaluation System (CURES), the investigators propose to review opioid poisonings over 12 months and send letters to prescribers in California when at least...

What is the current status of trial NCT03856593?

This trial is currently completed. It is a NA study. The enrollment target is 541 participants. The study started on 2019-04-05. Estimated completion is 2021-08-08.

What interventions are being tested in trial NCT03856593?

The interventions under investigation include: Standard letter (BEHAVIORAL), Comparator letter (BEHAVIORAL).

Who is sponsoring clinical trial NCT03856593?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03856593's enrollment target sits among peer trials

541 187th of 2000 higher than 1,814 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04929223 · 542 participants · Phase 1

    A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  • NCT05584670 · 542 participants · Phase 1

    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

  • NCT04557462 · 540 participants · Phase 3

    A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  • NCT04956640 · 540 participants · Phase 1

    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03856593, the US trial registry maintained by the National Library of Medicine. NCT03856593 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.